Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1182/blood-2014-01-492256 http://scihub22266oqcxt.onion/10.1182/blood-2014-01-492256 C3990911!3990911!24578503     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=24578503&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Blood 2014 ; 123 (16): 2470-7 Nephropedia Template TP {{tp|p=24578503|t=2014. Immunotoxins for leukemia |pdf=|usr=}}{{24578503}} gab.com Text Immunotoxins for leukemia JO: Blood http://www.kidney.de/pget.php?&tw=1&pmid=24578503 #FOAvip Unconjugated monoclonal antibodies that target hematopoietic differentiation antigens have been developed to treat hematologic malignancies. Although some of these have activity against chronic lymphocytic leukemia and hairy cell leukemia, in general, monoclonal antibodies have limited efficacy as single agents in the treatment of leukemia. To increase their potency, the binding domains of monoclonal antibodies can be attached to protein toxins. Such compounds, termed immunotoxins, are delivered to the interior of leukemia cells based on antibody specificity for cell surface target antigens. Recombinant immunotoxins have been shown to be highly cytotoxic to leukemic blasts in vitro, in xenograft model systems, and in early-phase clinical trials in humans. These agents will likely play an increasing role in the treatment of leukemia. Twit Text FOAVip Immunotoxins for leukemia ????Blood http://www.kidney.de/pget.php?&tw=1&pmid=24578503 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=24578503 #FOAvip English Wikipedia <ref>{{Cite pmid|24578503}}</ref> Immunotoxins for leukemia #MMPMID24578503 Wayne AS; FitzGerald DJ; Kreitman RJ; Pastan I Blood 2014[Apr]; 123 (16): 2470-7 PMID24578503show ga Unconjugated monoclonal antibodies that target hematopoietic differentiation antigens have been developed to treat hematologic malignancies. Although some of these have activity against chronic lymphocytic leukemia and hairy cell leukemia, in general, monoclonal antibodies have limited efficacy as single agents in the treatment of leukemia. To increase their potency, the binding domains of monoclonal antibodies can be attached to protein toxins. Such compounds, termed immunotoxins, are delivered to the interior of leukemia cells based on antibody specificity for cell surface target antigens. Recombinant immunotoxins have been shown to be highly cytotoxic to leukemic blasts in vitro, in xenograft model systems, and in early-phase clinical trials in humans. These agents will likely play an increasing role in the treatment of leukemia. äImmunotoxins for leukemia (epmc).pdf DeepDyve Pubget Overpricing